Here are five insights:
1. In his new role, Mr. O’Donnell will work with the company’s partner, Zimmer Biomet, to expand sales of Bonesupport’s Cerament Bone Void Filler.
2. Mr. O’Donnell will also be in charge of introducing Cerament G, a gentamicin eluting bone graft substitute, to the U.S. market, following trial outcomes.
3. Researchers will test Cerament G in the FORTIFY pre-market approval trial.
4. Prior to taking on this role, Mr. O’Donnell co-founded and served as CEO of ProteoThera, based in Cambridge, Mass.
5. Bonesupport offers injectable bioceramic bone graft substitutes to treat bone voids.
More articles on devices:
Where do our nation’s politicians stand on the medical device tax?
Zimmer Biomet, Stryker, Wright Medical Group & more: 12 key notes
K2M exceeds estimates with Q3 2016 earnings — 5 highlights
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
